300+ investors in your industry, stage, and region Get
Any industry
Google
Clean Energy
EdTech
Artificial Intelligence
Local
Enterprise Software
Travel
Platforms
InsurTech
Oil and Gas
Retail
Social Impact
Film
Cryptocurrency
SaaS
Restaurants
Photography
Payments
Email
CleanTech
Energy
Marketplace
Organic Food
Fitness
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
Social Network
Blockchain
B2B
Video Games
Big Data
Medical Device
Wellness
Education
Mobile
Automotive
Sports
Legal
eSports
Construction
Hospitality
Biotechnology
Consumer
Software
Renewable Energy
Crowdfunding
Theatre
Medical
Recruiting
Web3
Venture Capital
Fashion
Social
Beauty
Infrastructure
Cannabis
LGBT
Celebrity
Climate
Mobile Apps
Life Science
Wine and Spirits
Food and Beverage
Publishing
Music
Art
Real Estate
Sporting Goods
Manufacturing
Digital Media
FinTech
Finance
Financial Services
Social Media
Franchise
Mobile Advertising
Non Profit
Internet
Android
Sustainability
Hardware
Biotech
Impact
Proptech
Transportation
Enterprise
Community
Media (Entertainment)
Any country
Hong Kong
Thailand
United Arab Emirates
Egypt
Greece
Croatia
Burkina Faso
South Korea
Singapore
Brazil
Kyrgyzstan
LATAM
Africa
Oceania
Gibraltar
Liberia
Taiwan
Tunisia
Sweden
Zimbabwe
Mexico
Zambia
Nigeria
Russian Federation
Norway
Togo
Guinea
Nepal
Iran
Isle of Man
Madagascar
Pakistan
Tajikistan
Romania
Oman
Puerto Rico
Poland
Andorra
Cameroon
Guernsey
Sudan
Colombia
China
Armenia
Czech Republic
Costa Rica
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Australia
New Zealand
Morocco
Sri Lanka
Saudi Arabia
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Malawi
Myanmar
Uganda
Turkey
Uruguay
Jamaica
Paraguay
Moldova
Seychelles
Botswana
Japan
Ireland
Canada
South Africa
United Kingdom
France
Georgia
Denmark
Ghana
Iraq
Mali
Latvia
Malaysia
Portugal
Philippines
Sierra Leone
Rwanda
El Salvador
Senegal
Tanzania
Germany
India
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Argentina
Spain
Angola
Europe
Cyprus
Qatar
Belgium
Barbados
Bangladesh
Jordan
Austria
Ethiopia
Azerbaijan
Bulgaria
Ecuador
Bahamas
Faroe Islands
Estonia
Jersey
Bahrain
Bolivia
Algeria
Belize
Finland
Italy
Belarus
Hungary
Grenada
Israel
Iceland
Cambodia
Honduras
Lithuania
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
Karl Landert, CEO at Clinpal

Karl Landert

CEO @ Clinpal

Zürich, Switzerland

Karl Landert is a seed investor at Clinpal in Zürich focused on Medical and Health Care. Karl is the CEO and investor in eClinicalHealth, as well as the Chairman of the Board and an advisor to Clinpal and key customers. Karl’s career started at IBM in 1985. He was the founder of the IBM ClinWare Solution Unit, one of the first EDC systems for clinical trials in the mid-nineties. Between 1998 and 2001 he worked at Novartis as ChiefInformation Officer. His career continued at Credit Suisse, where he assumed several senior leadership positions in IT. He became CIO of the Group in 2008 and was a Member of the Executive Board of Credit-Suisse until 2012. In his functions at Credit-Suisse he oversaw hundreds of global change programs. In 2012 and 2013 Karl advised the Chairman of Credit-Suisse in setting up an innovation program for the firm. After retiring from Credit-Suisse in March 2013 Karl focused on a portfolio of investments in start-up companies, continues to advise Senior Leaders and is a Non-Executive director in technology companies. As of November 2015 Karl has taken on the role of CEO and dedicates his energy to eClinicalHealth where he defines and manages the direction of the company.

Total investments:
2
Last investment:
Lead investor:
50%

Last updated:

Industries Karl Landert invests in

MedicalHealth CareSoftwareClinical TrialsInformation Technology

Stages Karl Landert invests in

SeedSeries B

Countries Karl Landert invests in

SwitzerlandUnited Kingdom

Investment Focus

Industry

  • Medical 2 (100%)
  • Health Care 2 (100%)
  • Software 1 (50%)
  • Clinical Trials 1 (50%)
  • Information Technology 1 (50%)

Stage

  • Seed 1 (50%)
  • Series B 1 (50%)

Country

  • Switzerland 1 (50%)
  • United Kingdom 1 (50%)

Investments

CompanyDescriptionRoundLinks
Clinpal Clinpal
eClinicalHealth are a technology and consulting company providing solutions for the clinical trials industry. The company has developed a technology solution called Clinpal: Clinpal is a patient-centric, cloud-enabled platform that improves patient engagement and data acquisition through every step of the clinical trial journey. Clinpal allowsclinical trials get closer to the patient, improving trial efficiency, patient retention and helps capture high quality data in real time. The platform features a comprehensive workflow and communication engine for all stakeholders, including sites, patients CRAs and sponsors, which improves efficiency through the trial lifecycle. Clinpal’s data exchange capabilities enable the platform to act as an intelligent data hub, consolidating and enhancing biometric data with eSource reported directly by patients or clinicians. The scalable cloud architecture, automated configuration and flexible licensing models make these capabilities a viable choice across a wide range of clinical trials. $2.8M / Series B / Sep 11, 2014
Medical Insights Medical Insights
Medical Insight's mission is to create an open medical community platform which serves Health Care Professionals (HCP) of various specialties, international medical foundations and its medical industry partners with targeted personalized knowledge, education and communication services. Seed / Jul 02, 2013

Co-Investors

Clinpal

About Clinpal

VC Fund · Stirling, United Kingdom

eClinicalHealth are a technology and consulting company providing solutions for the clinical trials industry. The company has developed a technology solution called Clinpal: Clinpal is a patient-centric, cloud-enabled platform that improves patient engagement and data acquisition through every step of the clinical trial journey. Clinpal allowsclinical trials get closer to the patient, improving trial efficiency, patient retention and helps capture high quality data in real time. The platform features a comprehensive workflow and communication engine for all stakeholders, including sites, patients CRAs and sponsors, which improves efficiency through the trial lifecycle. Clinpal’s data exchange capabilities enable the platform to act as an intelligent data hub, consolidating and enhancing biometric data with eSource reported directly by patients or clinicians. The scalable cloud architecture, automated configuration and flexible licensing models make these capabilities a viable choice across a wide range of clinical trials.

Clinpal Contacts

NameEmailPhoneSocials
Ian Mills
Ian Mills Director of Software Engineering and Co-Founder

Sign up to unlock verified contacts

Unlock Contacts

3 more contacts available

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Google
Clean Energy
EdTech
Artificial Intelligence
Local
Enterprise Software
Travel
Platforms
InsurTech
Oil and Gas
Retail
Social Impact
Film
Cryptocurrency
SaaS
Restaurants
Photography
Payments
Email
CleanTech
Energy
Marketplace
Organic Food
Fitness
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
Social Network
Blockchain
B2B
Video Games
Big Data
Medical Device
Wellness
Education
Mobile
Automotive
Sports
Legal
eSports
Construction
Hospitality
Biotechnology
Consumer
Software
Renewable Energy
Crowdfunding
Theatre
Medical
Recruiting
Web3
Venture Capital
Fashion
Social
Beauty
Infrastructure
Cannabis
LGBT
Celebrity
Climate
Mobile Apps
Life Science
Wine and Spirits
Food and Beverage
Publishing
Music
Art
Real Estate
Sporting Goods
Manufacturing
Digital Media
FinTech
Finance
Financial Services
Social Media
Franchise
Mobile Advertising
Non Profit
Internet
Android
Sustainability
Hardware
Biotech
Impact
Proptech
Transportation
Enterprise
Community
Media (Entertainment)
Any country
Hong Kong
Thailand
United Arab Emirates
Egypt
Greece
Croatia
Burkina Faso
South Korea
Singapore
Brazil
Kyrgyzstan
LATAM
Africa
Oceania
Gibraltar
Liberia
Taiwan
Tunisia
Sweden
Zimbabwe
Mexico
Zambia
Nigeria
Russian Federation
Norway
Togo
Guinea
Nepal
Iran
Isle of Man
Madagascar
Pakistan
Tajikistan
Romania
Oman
Puerto Rico
Poland
Andorra
Cameroon
Guernsey
Sudan
Colombia
China
Armenia
Czech Republic
Costa Rica
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Australia
New Zealand
Morocco
Sri Lanka
Saudi Arabia
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Malawi
Myanmar
Uganda
Turkey
Uruguay
Jamaica
Paraguay
Moldova
Seychelles
Botswana
Japan
Ireland
Canada
South Africa
United Kingdom
France
Georgia
Denmark
Ghana
Iraq
Mali
Latvia
Malaysia
Portugal
Philippines
Sierra Leone
Rwanda
El Salvador
Senegal
Tanzania
Germany
India
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Argentina
Spain
Angola
Europe
Cyprus
Qatar
Belgium
Barbados
Bangladesh
Jordan
Austria
Ethiopia
Azerbaijan
Bulgaria
Ecuador
Bahamas
Faroe Islands
Estonia
Jersey
Bahrain
Bolivia
Algeria
Belize
Finland
Italy
Belarus
Hungary
Grenada
Israel
Iceland
Cambodia
Honduras
Lithuania
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Karl Landert invest in?

Karl Landert invests primarily in Medical, Health Care and Software startups, most often at Seed and Series B stage. Most of the 2 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.

When did Karl Landert last invest?

The most recent investment recorded for Karl Landert closed in Sep 2014. Shizune tracks 2 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Karl Landert Karl Landert Find email